Latest NewsSep 25, 2025HiFiBiO Therapeutics to Present Updated Phase 1 Clinical Data of Two Immuno-Oncology Programs at the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO) All Filter By: Year20252024202320222021202020192018201720162015Sep 5, 2022HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB301001 at 2022 ESMO CongressAug 15, 2022HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid TumorsApr 27, 2022HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingApr 18, 2022HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatmentApr 18, 2022Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors< 1 … 4 5 6 7 8 … 18 >
